Killer Migraine
ironjustice
Stroke
http://medinewsdirect.com/?p=725
November 23, 2009
A recent systematic review and meta-analysis performed by Harvard
Medical
School researchers reports that people suffering from migraine with
aura
(MA) have a two-fold increased risk for ischemic stroke.
Furthermore, the study suggests a magnified risk among migraineurs
who
are <45 years of age, smokers, and among women using oral
contraceptives.
The study results are published in the recent online issue of the
British
Medical Journal.
--------------
One might notice the **erythrocytosis** link.
Smoking and contraceptives.
THAT is why migraineurs also tend to DIE when flying.
The increased red blood cell count induced by ALTITUDE
compounded UPON the ALREADY increased red blood
cells from smoking and / or contraceptives KILLS ya ..
--------------------------------------------------------------------------------
Long flights cause altitude sickness
6 Jul 2007, 0002 hrs IST,REUTERS
BOSTON: Feeling a little achy, light headed or short of breath on a
long plane flight? A new study suggests you might be suffering from a
mild form of altitude sickness.
Until now, such symptoms had been attributed to jet lag, dehydration,
air contamination or being stuck in a cramped seat for hours.
Researchers report that true altitude sickness - with its nausea,
vomiting and sleep disturbances - was no more likely in volunteers in
simulated airplane cabins where the pressure was equivalent to 8,000
feet above sea level than it was when the pressure was closer to sea
level.
But after three hours of exposure to cabin pressures equivalent to
7,000 to 8,000 feet, the simulated fliers were more likely than
others to report backaches, headaches, shortness of breath, light-
headedness
and impaired coordination.
Women and younger people were the most likely to experience symptoms.
"On the basis of our findings, we conclude that maintaining a cabin
altitude of 6,000 feet or lower (equivalent to a barometric pressure
of 609 mm Hg or higher) on long-duration commercial flights will
reduce the discomfort among passengers," wrote Michael Muhm and
colleagues.
-----------------------------------
Briefs: Flying may pose risk to sleep apnea sufferers
By Times Staff, Wires
In print: Friday, May 23, 2008
Flying may pose risk to sleep apnea sufferers
People with severe obstructive sleep apnea (OSA) taking airline
flights may have a greater risk from cardiac stress than healthy
people, according to new research.
The scientists compared oxygen levels and breathing by simulating
flight conditions.
"It is normal for the rate of breathing to increase when air pressure
falls,'' said Leigh Seccombe, an Australian scientist.
"We found that (for those with OSA), their breathing intensity
increases at about the same rate as it does in healthy people." But
the physiological stress and demand for oxygen was increased in
people
with OSA.
"The work they do to run the core range of body functions (heart,
lungs, brain) is much greater under cabin conditions.''
Who loves ya.
Tom
Jesus Was A Vegetarian!
http://tinyurl.com/2r2nkh
Man Is A Herbivore!
http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk
ironjustice
Review Shows that Migraine with Aura Poses a High Risk for Ischemic
Stroke <<
Just in case ..
"Functional recovery of patients with cerebral stroke"
Choline alphoscerate in cognitive decline and in acute
cerebrovascular
disease: an analysis of published clinical data.
Mech Ageing Dev. 2001 Nov;122(16):2041-55.
Parnetti L, Amenta F, Gallai V.
Mech Ageing Dev. 2001 Nov;122(16):2041-55.
Department of Neuroscience, University of Perugia,
Via E Dal Pozzo, 06126, Perugia, Italy. parnetti.unipg.it
This paper has reviewed the documentation on the clinical
efficacy of choline alphoscerate, a cholinergic precursor,
considered as a centrally acting parasympathomimetic drug in
dementia disorders and in acute cerebrovascular disease.
Thirteen published clinical trials, examining in total 4054
patients, have evaluated the use of choline alphoscerate in
various forms of dementia disorders of degenerative, vascular
or combined origin, such as senile dementia of the Alzheimer's
type (SDAT) or vascular dementia (VaD) and in acute
cerebrovascular diseases, such as transitory ischemic attack
(TIA) and stroke.
Analysis has assessed the design of each study, in particular
with respect to experimental design, number of cases, duration
of treatment and tests used to evaluate drug clinical efficacy.
Most of the ten studies performed in dementia disorders were
controlled trials versus a reference drug or placebo.
Overall, 1570 patients were assessed in these studies, 854 of
which in controlled trials.
As detected by validated and appropriate tests, such as Mini
Mental State Evaluation (MMSE) in SDAT and Sandoz Clinical
Assessment Geriatric (SCAG) in VaD, administration of choline
alphoscerate significantly improved patient clinical condition.
Clinical results obtained with choline alphoscerate were superior
or equivalent to those observed in control groups under active
treatment and superior to the results observed in placebo groups.
Analysis stresses the clear internal consistency of clinical data
gathered by different experimental situations on the drug effect,
especially with regard to the cognitive symptoms (memory, attention)
characterising the clinical picture of adult-onset dementia
disorders.
The therapeutic usefulness of choline alphoscerate in relieving
cognitive symptoms of chronic cerebral deterioration differentiates
this drug from cholinergic precursors used in the past, such as
choline and lecithin.
Three uncontrolled trials were performed with choline alphoscerate
in acute cerebrovascular stroke and TIA, totalling 2484 patients.
The results of these trials suggest that this drug might favour
functional recovery of patients with cerebral stroke and should
be confirmed in future investigations aimed at establish the
efficacy of the drug in achieving functional recovery of patients
with acute cerebrovascular disease.
PMID: 11589921